viewAnteris Technologies Ltd

Anteris Technologies to present at Credit Suisse Structural Heart Sessions next week

The company is focused on developing next-generation technologies that help healthcare professionals create life-changing outcomes for patients.

Anteris Technologies Ltd - Anteris Technologies to present at Credit Suisse Structural Heart Sessions next week
DurAVR™ is a 3D single-piece aortic valve for the treatment of aortic stenosis.

Anteris Technologies Ltd (ASX:AVR) will take part in a forum hosted by Credit Suisse next week featuring technologies that address major structural heart indications in which it will outline its proprietary ADAPT® tissue platform.

The symposium, ‘Credit Suisse Virtual Structural Heart Sessions,’ will feature new companies in the structural heart disease space who are developing disruptive solutions for large market opportunities.

These include Transcatheter Aortic Valve Replacement (TAVR) and Surgical Aortic Valve Replacement (SAVR) procedures, among others.

The three-hour event will be held virtually on Monday, November 23, 2020, at 10am US ET (November 24, 2020, at 2am AEDT) and will be moderated by Credit Suisse senior analyst Matt Miksic.

Proprietary ADAPT® tissue platform

Anteris chief executive officer Wayne Paterson will provide an overview of the company’s proprietary ADAPT® tissue platform which is the technology behind DurAVR™, a unique 3D single-piece aortic valve that features superior durability with 10-year ‘no-calcification’ data.

Besides this, Bart Meuris, chief of cardiovascular surgery at University Hospitals, Leuven (Belgium), will present key interim findings from the trials’ early results which so far, have exceeded expectations.

Trial observations

Key observations from this trial include:

  • DurAVR™ can restore normal pre-disease hemodynamics and has the potential to be a functional cure for the treatment of severe aortic stenosis;
  • Patient recovery was swift, and no stay in an intensive care unit was needed; and
  • This technology, with both surgical and transcatheter options, offers a potentially more durable solution for enhancing acute and long-term outcomes for patients with aortic valve disease.

“Important innovation”

Paterson said: “We are grateful and excited to be selected to participate in this forum to further bolster the profile of DurAVR™, which truly represents an important innovation that will impact the entire structural heart market due to the valve’s superior hemodynamic profile.”

Quick facts: Anteris Technologies Ltd

Price: 3.67 AUD

Market: ASX
Market Cap: $21.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Anteris Technologies CEO hails 'very good results' from DurAVR™ human study

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson caught up with Proactive's Andrew Scott soon after reporting that early results from its first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a...

on 19/10/20

2 min read